10 recruiting, 8 completed, 2 not yet recruiting, 1 enrolling by invitation. 8 Not applicable, 8 Phase 2, 4 Phase 1, 2 Phase 3, 1 Early Phase 1.
Follow Nicotinamide Riboside (NR): new trials by email Literature Review of Nicotinamide Riboside (NR) trials Research Report on Nicotinamide Riboside (NR)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The NICE-PAD II Trial Nicotinamide Riboside (NR), Placebo - Peripheral Artery Disease (PAD) | Phase 3 | Not yet recruiting | Northwestern University | 250 | 2026-12-01 | 2026-08-24 |
| Nicotinamide Riboside Supplementation in Chronic Kidney Disease Nicotinamide Riboside (NR), Matched Placebo (Capsules) - Chronic Kidney Disease | Phase 2 | Not yet recruiting | University of California, San Diego | 30 | 2026-10-01 | 2026-07-15 |
| N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease Nicotinamide Riboside (NR), Palacebo - Alzheimer Disease (AD) | Phase 2 | Recruiting | Haukeland University Hospital | 270 | 2026-08-26 | 2026-08-20 |
| Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants Nicotinamide Riboside (NR), Placebo - Preterm Birth, Inadequate Milk Production | Phase 2 / Phase 3 | Recruiting | University of California, Davis | 40 | 2026-08-19 | 2026-09-14 |
| NAD Supplementation in Parkinson's Disease Nicotinamide Riboside (NR), Oral placebo capsules - Parkinson's Disease | Not applicable | Enrolling by invitation | University of Oklahoma | 40 | 2026-08-10 | 2026-08-12 |
| Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension Nicotinamide Riboside (NR), Placebo - Pulmonary Hypertension | Not applicable | Recruiting | Vanderbilt University Medical Center | 10 | 2026-04-09 | 2026-05-04 |
| Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training Nicotinamide Riboside (NR) - Health Adult Subjects | Not applicable | Recruiting | ZHANG Jiaqi | 16 | 2026-01-06 | 2026-03-18 |
| Effects of Single-Dose Nicotinamide Riboside (NR) on Sleep Nicotinamide Riboside (NR), Placebo - Healthy Volunteers | Not applicable | Completed | Eye & ENT Hospital of Fudan University | 28 | 2025-12-17 | 2026-09-16 |
| NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals Nicotinamide Riboside (NR), Placebo - Sleep | Phase 2 | Recruiting | Haukeland University Hospital | 16 | 2025-10-13 | 2025-09-15 |
| The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease Nicotinamide Riboside (NR), Placebo - Huntington Disease | Phase 2 | Recruiting | Oslo University Hospital | 120 | 2025-03-18 | 2025-03-19 |
| The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging Nicotinamide Riboside (NR), Placebo - Frailty, Frail Elderly Syndrome | Phase 2 | Recruiting | Haukeland University Hospital | 100 | 2025-01-01 | 2025-01-20 |
| Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS) Nicotinamide riboside (NR) - Smooth Muscle Dysfunction Syndrome (SMDS) | Phase 1 | Recruiting | The University of Texas Health Science Center, Houston | 15 | 2024-03-06 | 2025-09-12 |
| Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity Nicotinamide Riboside (NR), Placebo - Healthy Aging, Lifestyle-related Condition | Not applicable | Recruiting | Finis Terrae University | 28 | 2024-03-01 | 2025-07-11 |
| Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid Nicotinamide Riboside (NR), Mind-body reprocessing therapy (MBRT), Care as usual - Long COVID | Phase 2 | Completed | University Hospital, Akershus | 310 | 2023-01-30 | 2026-08-25 |
| NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy Nicotinamide Riboside (NR), nicotinamide mononucleotide - Healthy | Phase 1 | Completed | Haukeland University Hospital | 12 | 2022-09-17 | 2025-01-17 |
| Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults Nicotinamide (NAM), Nicotinamide Riboside (NR), Nicotinamide Mono Nucleotide (NMN) - Healthy | Not applicable | Completed | Société des Produits Nestlé (SPN) | 68 | 2022-07-12 | 2025-04-24 |
| NR Supplementation and Exercise Niagen, Exercise - Overweight and Obesity, Aging | Not applicable | Completed | Maastricht University Medical Center | 30 | 2021-08-10 | 2023-02-10 |
| Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial) Walking Exercise, Nicotinamide Riboside (NR) - Hypertension | Phase 1 | Completed | University of Florida | 147 | 2020-07-28 | 2024-06-06 |
| Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation Nicotinamide riboside (NR) - Allogeneic Hematopoietic Cell Transplantation | Early Phase 1 | Recruiting | Case Comprehensive Cancer Center | 20 | 2020-05-19 | 2026-08-06 |
| Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome Nicotinamide Riboside (NR) - Cancer, Skin Fibroblasts | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2019-03-25 | 2020-12-08 |
Showing 20 of 21. Sign in to see all of them.
Alzheimer Disease (1) · Aortic Aneurysm, Thoracic (1) · Atherosclerosis (1) · Cerebrovascular Disorders (1) · Cognitive Dysfunction (1) · Coronary Artery Disease (1) · Dementia (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Disease (1) · Fasting (1) · Frailty (1) · Huntington Disease (1) · Hypertension (1) · Hypertension, Pulmonary (1)
Haukeland University Hospital (4) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Case Comprehensive Cancer Center (1) · Eye & ENT Hospital of Fudan University (1) · Finis Terrae University (1) · Maastricht University Medical Center (1) · Northwestern University (1) · Oslo University Hospital (1) · Société des Produits Nestlé (SPN) (1) · The University of Texas Health Science Center, Houston (1) · University Hospital, Akershus (1) · University of California, Davis (1) · University of California, San Diego (1) · University of Florida (1) · University of Oklahoma (1)
United States (9) · Norway (6) · China (2) · Chile (1) · Netherlands (1) · Switzerland (1)
Charalampos Tzoulis, PhD (2) · Andriy Yabluchanskiy, MD, PhD (1) · Armin Ahmadi, PhD (1) · Charalampos Tzoulis, MD, PhD (1) · Dianna Milewicz, MD, PhD (1) · Evan L Brittain, MD (1) · Katarina Lundervold, MD (1) · Kristoffer Haugarvoll, MD, PhD (1) · Mary McDermott (1) · Michael N Sack, M.D. (1) · Paul M Hwang, M.D. (1) · Robert Mankowski, PhD (1) · Ronald Sobecks, MD (1)
PMID 20008425, PMID 27721479, PMID 29469929, PMID 29599478, PMID 29992272, PMID 30673618, PMID 30797625, PMID 31035376, PMID 31278280, PMID 32421208, PMID 33769844, PMID 34084879, PMID 34292494, PMID 34871486, PMID 35025762, PMID 37478182, PMID 37586364, PMID 38987585, PMID 4060272, PMID 41540253, PMID 42063312, PMID 42843881
2023 (2), 2025 (1), K01DK147652 (1), R01AG090846 (1), R01HL163960 (1), R21AG064282 (1)